首页> 美国卫生研究院文献>Iranian Journal of Cancer Prevention >In Silico Design and Analysis of TGFαL3-SEB Fusion Protein as a New Antitumor Agent Candidate by Ligand-Targeted Superantigens Technique
【2h】

In Silico Design and Analysis of TGFαL3-SEB Fusion Protein as a New Antitumor Agent Candidate by Ligand-Targeted Superantigens Technique

机译:配体靶向超抗原技术对新型抗肿瘤药物候选TGFαL3-SEB融合蛋白进行计算机设计和分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundBacterial superantigen Staphylococcal Enterotoxins (SEs), has stimulated polyclonal T cells irrespective of their antigen specificity, resulted a massive release of cytokines, and suggested that they could be assigned as a candidate of new antitumor agents. Recent attempts have done to specifically target superantigens towards tumors, subsequently Monoclonal antibodies and tumor-related ligands have employed as targeting molecules of superantigen for the preclinical treatment of different tumors. Here, we have evaluated TGFαL3-SEB fusion protein as a new antitumor candidate by genetically fusing the third loop of transforming growth factor alpha (TGFαL3) to Staphylococcal Enterotoxin type B.
机译:背景细菌超抗原葡萄球菌肠毒素(SEs)已刺激多克隆T细胞,无论其抗原特异性如何,导致大量细胞因子释放,并建议将其指定为新的抗肿瘤药物的候选药物。最近已经进行了尝试将超抗原特异性地靶向肿瘤,随后单克隆抗体和肿瘤相关配体被用作超抗原的靶向分子,用于不同肿瘤的临床前治疗。在这里,我们通过将转化生长因子α(TGFαL3)的第三环遗传融合到B型葡萄球菌肠毒素中,评估了TGFαL3-SEB融合蛋白作为新的抗肿瘤候选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号